<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329640</url>
  </required_header>
  <id_info>
    <org_study_id>NP 17/2010 TraQ-Me 01</org_study_id>
    <nct_id>NCT01329640</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)</brief_title>
  <official_title>Phase II Feasibility Study of Weekly Paclitaxel Plus Weekly Trastuzumab Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide Plus Weekly Trastuzumab for Locally Advanced HER2-Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação Faculdade de Medicina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, effectiveness and cost-effectiveness of
      metronomic chemotherapy combined with trastuzumab as neoadjuvant therapy for locally advanced
      HER2-positive breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>INCIDENCE OF FEBRILE NEUTROPENIA</measure>
    <time_frame>18 weeks</time_frame>
    <description>INCIDENCE OF FEBRILE NEUTROPENIA WITH METRONOMIC SCHEDULE WILL BE NO HIGHER THAN 10%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TUMOR SIZE</measure>
    <time_frame>From the beginning of treatment until surgery, disease progression or death</time_frame>
    <description>Efficacy will be assessed by:
Tumor measurements using MRI of the Breast
Pathologic complete response
Progression-free survival
Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Locally Advanced HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel, trastuzumab, doxorrubicin, ciclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide</intervention_name>
    <description>Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;
Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks</description>
    <arm_group_label>Paclitaxel, trastuzumab, doxorrubicin, ciclophosphamide</arm_group_label>
    <other_name>Metronomic chemotherapy with trastuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of locally advanced breast cancer

          -  T &gt; 2 cm (any N), or any T and positive node(needle biopsy is required if tumor size
             is less than 2cm)

          -  Non-metastatic disease confirmed by computerized tomography and bone scan

          -  HER2 positive by IHC (+++) and/or Fish (+) according to international definitions
             (ASCO 2007)

          -  Normal left ventricular ejection fraction (LVEF)

          -  Indication of preoperative chemotherapy

          -  multifocal tumors acceptable provided that the largest tumor is Her2-positive

          -  ECOG 0-1

        Exclusion Criteria:

          -  Another malignancy within the last 5 years (except curatively treated skin carcinoma,
             in situ cervix carcinoma, in situ ductal carcinoma of the breast, or in situ lobular
             carcinoma of the breast)

          -  Clinically significant comorbidities such as cardiovascular diseases, COPD, renal or
             liver impairment, psychiatric disorders

          -  LVEF value below institutional limits of normal range

          -  Detected or suspected distant metastasis

          -  Neutrophils lower than 1,500/µL, platelets lower than 100,000/µL, hemoglobin lower
             than 10 g/dL, AST higher than 2.5x upper limit of normal (ULN), total bilirubin higher
             than ULN, alkaline phosphatase more than 1.5x ULN
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metronimic chemotherapy</keyword>
  <keyword>Locally Advanced HER2-positive Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

